Aquestive Therapeutics, Inc.
NASDAQ:AQSTDrug Manufacturers - Specialty & Generic
+$0.23 today
- Market cap
- $475.10M
- Beta
- 1.45
- P/E (TTM)
- -8.3
- EPS (TTM)
- -$0.56
Volume 1.80M
Average 1.51M
AQST Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Aquestive Therapeutics, Inc.NASDAQ: AQST
Operating Expenses · Q1 FY2026 · quarter ended Mar 2026
Operating expenses dips below year-ago levels
Q1 FY2026 operating expenses of $15.18M fell 37.9% year over year, behind the +12.2% change in trailing-twelve-month operating expenses. Sequentially, it fell 57.9% from the prior quarter. Over 3 fiscal years it compounded at +11.3% a year.
Context
- Operating expenses amounted to 217.8% of revenue in FY2025, up 95.4 pp from a year earlier.
- Operating expenses increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -37.9% toward the trailing-twelve-month pace of +12.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 97.04M USD
- Year-over-year change
- +37.7%
- 4-year CAGR
- +8.3%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 97.04M | +37.7% |
| FY2024 | 2024-12-31 | 70.46M | +57.1% |
| FY2023 | 2023-12-31 | 44.85M | -36.3% |
| FY2022 | 2022-12-31 | 70.36M | -0.2% |
| FY2021 | 2021-12-31 | 70.52M | — |
Operating Expenses vs competitors
How AQST compares with its peers on the latest reported figures
- AQST's LTM Mar 2026 operating expenses of $87.79M is the 8th highest of the 10 companies compared; the peer median is $224.39M.
- Its year-over-year change of +12.2% is the 7th highest of 10, against a peer median of +28.7%.
- Operating expenses amounts to 174.6% of revenue for AQST, versus a peer median of 79.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $1.39B | +46.2% | +4.5% | 79.2% | |
| LTM Jun 2026 | $844.11M | +60.9% | +8.5% | 101.6% | |
| LTM Mar 2026 | $361.73M | +36.9% | +16.5% | 166.1% | |
| LTM Mar 2026 | $293.27M | +21.6% | +16.2% | 36.8% | |
| LTM Mar 2026 | $224.39M | +28.7% | +15.1% | 31.1% | |
| LTM Mar 2026 | $220.98M | +9.0% | +8.0% | 70.2% | |
| LTM Mar 2026 | $153.37M | +47.6% | +21.5% | 125.4% | |
| LTM Mar 2026 | $87.79M | +12.2% | +11.3% | 174.6% | |
| LTM Mar 2026 | $45.41M | +5.0% | -14.0% | 70.2% | |
| LTM Mar 2026 | $41.98M | +10.7% | +1.7% | 100.1% | |
| Peer median (excluding AQST) | $224.39M | +28.7% | +8.5% | 79.2% | |
Competitors are the stored peer set for AQST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 50.83M | 47.68M | 50.58M | 57.56M | 44.55M |
| Cost of Revenue | 14.99M | 19.39M | 20.83M | 17.87M | 17.15M |
| Gross Profit | 35.84M | 28.29M | 29.75M | 39.69M | 27.39M |
| Gross Margin | 70.5% | 59.3% | 58.8% | 69.0% | 61.5% |
| Research & Development | 17.05M | 17.48M | 13.1M | 20.28M | 17.19M |
| Selling, General & Admin | 53.48M | 52.88M | 31.75M | 50.18M | 79.85M |
| Operating Expenses | 70.52M | 70.36M | 44.85M | 70.46M | 97.04M |
| Depreciation & Amortization | 2.96M | 2.39M | 1.35M | 718K | 559K |
| EBITDA | (45.11M) | (39.58M) | 1.18M | (26.62M) | (66.13M) |
| EBITDA Margin | -88.8% | -83.0% | 2.3% | -46.2% | -148.4% |
| Operating Income | (34.68M) | (42.07M) | (15.1M) | (30.77M) | (69.65M) |
| Operating Margin | -68.2% | -88.2% | -29.9% | -53.5% | -156.4% |
| Interest Income | 423K | 99K | 16.32M | 3.44M | 0 |
| Interest Expense | 22.46M | 12.44M | 7.46M | 16.82M | 17.1M |
| Other Income / Expenses | (35.86M) | (12.34M) | 7.48M | (13.38M) | (14.13M) |
| Income Before Tax | (70.54M) | (54.41M) | (7.63M) | (44.15M) | (83.78M) |
| Pre-Tax Margin | -138.8% | -114.1% | -15.1% | -76.7% | -188.1% |
| Income Tax Expense | 0 | 0 | 245K | (14K) | 0 |
| Net Income | (70.54M) | (54.41M) | (7.87M) | (44.14M) | (83.78M) |
| Net Margin | -138.8% | -114.1% | -15.6% | -76.7% | -188.1% |
| EPS (Basic) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| EPS (Diluted) | (1.85) | (1.12) | (0.13) | (0.51) | (0.76) |
| Weighted Avg Shares | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
| Weighted Avg Shares (Diluted) | 38.08M | 48.73M | 61.26M | 86.73M | 121.97M |
Aquestive Therapeutics, Inc.
NASDAQ:AQST
Intrinsic Alpha fair value
Locked
Current Price
$3.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.